一分钟看懂
这是一项关于多发性骨髓瘤的III 期研究，登记的药物或干预包括Motixafortide+G-CSF；Placebo+G-CSF，当前状态为招募中。登记地点显示中国北京、哈尔滨有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Motixafortide+G-CSF；Placebo+G-CSF · III 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Peking University People's Hospital · 北京
- Harbin The First Hospital · 哈尔滨
公开的入选条件
- * (Limit: 15,000 characters)
- 1. Patients must have a signed study informed consent prior to entering the study.
- 2. Patients must be between the ages of 18 and 78 years.
- 3. Diagnosis of active multiple myeloma (aMM) as defined by IMWG criteria.
- 4. At least one week (7 days) from last induction cycle of combination/multi-agent chemotherapy (e.g. KRD \[carfilzomib, lenalidomide, dexamethasone\] or VRD \[bortezomib, lenalidomide, dexamethasone\]) or from last single agent chemotherapy (e.g. lenalidomide
- 5. Eligible for Autologous Hematopoietic stem cell transplantation according to the Investigator's discretion.
- 6. The subjects should be in first or second CR (including CR and SCR) or PR (including PR and VGPR).
- 7. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06514508；登记信息更新于 2026-09-14。